Latanoprostene Bunod
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Latanoprostene Bunod: From Open-Angle Glaucoma to Visceral Calciphylaxis
One-Sentence Summary
Latanoprostene bunod is an eye-drop medicine originally used to lower eye pressure in open-angle glaucoma and ocular hypertension. The TxGNN model predicts it may be effective for visceral calciphylaxis, but there are currently no clinical trials and no publications supporting this specific prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Open-angle glaucoma; ocular hypertension (the Singapore licence record contains no indication text, so these are taken from the knowledge-graph indication data) |
| Predicted New Indication | Visceral calciphylaxis |
| TxGNN Prediction Score | 99.76% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, latanoprostene bunod is converted into two active parts: latanoprost acid (a prostaglandin F2-alpha analogue acting on the FP receptor) and nitric oxide (NO). Together these increase fluid drainage from the eye and lower intraocular pressure. Laboratory data also show that it increases guanylyl cyclase activity (NO-mediated cGMP formation).
The link to visceral calciphylaxis is weak. NO-mediated vasodilation could theoretically relate to calcific vasculopathy. However, calciphylaxis involves widespread vascular calcification and clotting, and an eye drop gives minimal systemic exposure. The prediction is therefore best viewed as a hypothesis from the model, not a mechanistically supported finding.
For context, the other top-ranked predictions are mostly vascular or thoracic outlet conditions with similarly weak rationale. The one exception is primary hereditary glaucoma (score 99.71%), which is mechanistically plausible but closely mirrors the existing glaucoma labelling, so it is not a novel repurposing signal. Efficacy in paediatric or developmental glaucoma, where drainage-pathway malformations may limit response, is unestablished.
Clinical Trial Evidence
Currently no related clinical trials registered for visceral calciphylaxis.
For reference, one trial was retrieved for the broader prediction "vascular disease" (rank 6):
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03931317 | Not applicable | Completed | 70 | Crossover comparison of latanoprostene bunod and timolol on eye pressure and retinal blood vessel density in ocular hypertension or primary open-angle glaucoma; addresses ocular blood vessels, not systemic vascular disease |
Literature Evidence
Currently no related literature available for visceral calciphylaxis.
For reference, publications retrieved for other predictions:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38113361 | 2023 | Case report | Ophthalmic Surg Lasers Imaging Retina | An 11-year-old with a port-wine birthmark, choroidal hemangioma and glaucoma developed serous retinal detachment on prostaglandin analogue therapy including latanoprostene bunod; it improved after stopping. This is a safety signal, not evidence of benefit (hemangioendothelioma prediction). |
| 30028313 | 2018 | Review | Neural Regen Res | Overview of treatment options for glaucomatous optic neuropathy; not direct evidence for vascular disease |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16214P | VYZULTA (Latanoprostene Bunod Ophthalmic Solution) 0.024% | Sterile solution | Not stated in the registration record |
Safety Considerations
- Drug Interactions: No drug-drug interactions were identified. The only entry is the drug's own pharmacological target, the prostanoid FP receptor.
- Case report signal: A paediatric patient with a port-wine birthmark and choroidal hemangioma developed serous retinal detachment on prostaglandin analogue therapy, so caution is warranted in patients with vascular malformations of the eye.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for visceral calciphylaxis is supported only by the model score (evidence level L5). There are no trials or publications, and the mechanism is implausible given minimal systemic exposure from topical eye dosing. The most credible prediction, primary hereditary glaucoma, is largely an extension of the existing label.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator (HSA)
- Detailed mechanism of action data
- Evidence that clinically relevant systemic or local exposure can be reached by a suitable route and formulation
- Preclinical or mechanistic studies linking NO or FP-receptor signalling to calcific vasculopathy
- For primary hereditary glaucoma, targeted studies in paediatric or developmental glaucoma, which could be pursued as a separate research question
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.